Allergy Therapeutics (LSE:AGY) — Stock Price
Allergy Therapeutics (LSE:AGY) is currently trading at GBX5.50 GBX, up 0.00% today. Over the past 52 weeks, shares have ranged between GBX5.00 and GBX12.10. This page tracks Allergy Therapeutics's live share price on the LSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see AGY market cap overview.
Allergy Therapeutics (AGY) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Allergy Therapeutics's daily closing share price and trading volume on the LSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Allergy Therapeutics Income Statement — Revenue, Profit & Earnings by Year
Allergy Therapeutics's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | GBX55.04 Million | GBX55.20 Million | GBX59.59 Million | GBX72.77 Million | GBX84.33 Million |
| Cost of Revenue | GBX29.91 Million | GBX25.46 Million | GBX26.90 Million | GBX23.81 Million | GBX22.53 Million |
| Gross Profit | GBX25.13 Million | GBX29.74 Million | GBX32.69 Million | GBX48.95 Million | GBX61.80 Million |
| Research & Development | GBX15.38 Million | GBX22.90 Million | GBX20.12 Million | GBX15.66 Million | GBX12.89 Million |
| SG&A | GBX19.09 Million | GBX22.79 Million | GBX25.18 Million | GBX20.83 Million | GBX20.67 Million |
| Total Operating Expenses | GBX54.63 Million | GBX64.99 Million | GBX72.90 Million | GBX61.95 Million | GBX59.16 Million |
| Operating Income | GBX-29.50 Million | GBX-35.26 Million | GBX-34.85 Million | GBX-13.00 Million | GBX4.03 Million |
| EBITDA | GBX-29.43 Million | GBX-30.74 Million | GBX-36.24 Million | GBX-8.69 Million | GBX7.61 Million |
| EBIT | GBX-33.60 Million | GBX-35.06 Million | GBX-40.46 Million | GBX-12.86 Million | GBX3.48 Million |
| Interest Expense | GBX6.84 Million | GBX3.88 Million | GBX2.44 Million | GBX541.00K | GBX386.00K |
| Income Before Tax | GBX-40.44 Million | GBX-39.17 Million | GBX-42.62 Million | GBX-13.40 Million | GBX3.66 Million |
| Income Tax Expense | GBX-312.00K | GBX1.05 Million | GBX1.30 Million | GBX1.12 Million | GBX771.00K |
| Net Income | GBX-40.13 Million | GBX-40.22 Million | GBX-43.07 Million | GBX-13.78 Million | GBX2.89 Million |
Allergy Therapeutics Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Allergy Therapeutics's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | GBX67.54 Million | GBX64.83 Million | GBX66.77 Million | GBX72.95 Million | GBX88.09 Million |
| Total Current Assets | GBX34.68 Million | GBX33.48 Million | GBX33.53 Million | GBX42.39 Million | GBX57.86 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | GBX200.00K | — | — | — |
| Net Receivables | GBX7.97 Million | GBX7.82 Million | GBX7.09 Million | GBX10.47 Million | GBX6.22 Million |
| Inventory | GBX13.91 Million | GBX12.74 Million | GBX11.59 Million | GBX11.41 Million | GBX10.84 Million |
| Property, Plant & Equipment | — | — | GBX23.98 Million | GBX20.19 Million | GBX19.72 Million |
| Goodwill | GBX3.33 Million | GBX3.32 Million | GBX3.35 Million | GBX3.35 Million | GBX3.34 Million |
| Total Liabilities | GBX95.74 Million | GBX61.12 Million | GBX64.70 Million | GBX35.18 Million | GBX39.55 Million |
| Total Current Liabilities | GBX27.19 Million | GBX20.55 Million | GBX18.57 Million | GBX18.05 Million | GBX18.23 Million |
| Long-term Debt | GBX53.04 Million | GBX22.50 Million | GBX26.85 Million | GBX1.50 Million | GBX2.45 Million |
| Net Debt | GBX47.50 Million | GBX18.07 Million | GBX21.14 Million | GBX-9.99 Million | GBX-29.10 Million |
| Total Stockholder Equity | GBX-28.19 Million | GBX3.71 Million | GBX2.07 Million | GBX37.77 Million | GBX48.53 Million |
| Retained Earnings | GBX-195.10 Million | GBX-198.93 Million | GBX-121.74 Million | GBX-78.41 Million | GBX-67.27 Million |
Allergy Therapeutics Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Allergy Therapeutics generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | GBX-28.72 Million | GBX-32.14 Million | GBX-30.92 Million | GBX-14.11 Million | GBX8.52 Million |
| Capital Expenditures | GBX3.26 Million | GBX3.40 Million | GBX4.67 Million | GBX3.06 Million | GBX2.56 Million |
| Free Cash Flow | GBX-31.98 Million | GBX-35.54 Million | GBX-35.59 Million | GBX-17.17 Million | GBX5.95 Million |
| Investing Cash Flow | GBX-3.15 Million | GBX-1.20 Million | GBX-4.67 Million | GBX-3.06 Million | GBX-2.76 Million |
| Financing Cash Flow | GBX32.04 Million | GBX31.43 Million | GBX29.91 Million | GBX-2.64 Million | GBX-2.03 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | GBX871.00K | GBX759.00K | GBX114.00K | GBX469.00K | GBX635.00K |
| Depreciation | GBX4.17 Million | GBX4.32 Million | GBX4.22 Million | GBX4.17 Million | GBX4.13 Million |
| Change in Cash | GBX-125.00K | GBX-1.93 Million | GBX-5.67 Million | GBX-19.76 Million | GBX3.31 Million |
Allergy Therapeutics Earnings History — EPS Actual vs. Analyst Estimates
Track Allergy Therapeutics's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 30, 2026 | — | — | — |
| Dec 11, 2025 | -0.01 | 0.00 | — |
| Sep 30, 2025 | 0.00 | 0.00 | — |
| Mar 31, 2025 | 0.00 | 0.00 | — |
| Sep 29, 2022 | -0.03 | -2.00 | +98.50% |
| Mar 03, 2022 | 0.01 | — | — |
| Sep 23, 2021 | -0.02 | — | — |
| Mar 01, 2021 | 0.02 | 0.00 | — |